Sartorius Stedim Biotech SA (OTCPK:SDMHF)

$ 195 0 (0%) Market Cap: 18.66 Bil Enterprise Value: 21.12 Bil PE Ratio: 168.91 PB Ratio: 4.63 GF Score: 94/100

Q3 2024 Sartorius AG and Sartorius Stedim Biotech SA Earnings Call Transcript
Oct 17, 2024

$221.5 (+9.79%)

Earnings
Q2 2024 Sartorius AG and Sartorius Stedim Biotech SA Earnings Call Transcript
Jul 18, 2024

$190 (+7.83%)

Earnings
Q3 2023 Sartorius AG and Sartorius Stedim Biotech SA Earnings Call Transcript
Oct 19, 2023

$199.89

Earnings
Q2 2023 Sartorius AG and Sartorius Stedim Biotech SA Earnings Call Transcript
Jul 21, 2023

$297 (+8.08%)

Earnings
Q1 2023 Sartorius AG and Sartorius Stedim Biotech SA Earnings Call Transcript
Apr 20, 2023

$287.25 (-7.19%)

Earnings
Sartorius Stedim Biotech SA, Polyplus Co Ltd - to Discuss the acquisition of Polyplus Call Transcript
Apr 05, 2023
Sartorius Stedim Biotech SA Annual Shareholders Meeting Transcript
Mar 27, 2023
Q4 2022 Sartorius AG and Sartorius Stedim Biotech SA Earnings Call Transcript
Jan 26, 2023

$332.1

Earnings
Q3 2022 Sartorius AG Earnings Call Transcript
Oct 19, 2022

$324.95

Earnings
Q2 2022 Sartorius AG Earnings Call Transcript
Jul 21, 2022

$328

Earnings
Q1 2022 Sartorius AG Earnings Call Transcript
Apr 21, 2022

$373.35 (+3.92%)

Earnings
Sartorius Stedim Biotech SA Annual Shareholders Meeting Transcript
Mar 29, 2022
Q4 2021 Sartorius AG Earnings Call Transcript
Jan 27, 2022

$409.49

Earnings
Q3 2021 Sartorius AG Earnings Call Transcript
Oct 20, 2021

$546.43

Earnings
Q2 2021 Sartorius AG and Sartorius Stedim Biotech SA Earnings Call Transcript
Jul 21, 2021

$516.05 (-4.53%)

Earnings
Q1 2021 Sartorius AG and Sartorius Stedim Biotech SA Earnings Call Transcript
Apr 21, 2021

$460.55

Earnings
Sartorius Stedim Biotech SA Annual Shareholders Meeting (French) Transcript
Mar 24, 2021
Q4 2020 Sartorius AG and Sartorius Stedim Biotech SA Earnings Call Transcript
Jan 27, 2021

$403 (-2.49%)

Earnings
Q3 2020 Sartorius AG Earnings Call Transcript
Oct 20, 2020

$385.25 (+6.42%)

Earnings
Q2 2020 Sartorius AG Earnings Call Transcript
Jul 21, 2020

$279.95

Earnings
Sartorius Stedim Biotech SA Annual Shareholders Meeting Transcript
Jun 24, 2020
Q1 2020 Sartorius AG Earnings Call Transcript
Apr 21, 2020

$230 (+12.77%)

Earnings
Preliminary Q4 2019 Sartorius AG Earnings Call Transcript
Jan 28, 2020

$170

Earnings
Nine Months 2019 Sartorius AG Earnings Call Transcript
Oct 21, 2019

$139.5

Earnings
Half Year 2019 Sartorius AG Earnings Call Transcript
Jul 19, 2019

$154.5

Earnings
Q1 2019 Sartorius AG Earnings Call Transcript
Apr 18, 2019

$122.63

Earnings

Q4 2022 Sartorius AG and Sartorius Stedim Biotech SA Earnings Call Transcript

Jan 26, 2023 / 02:30PM GMT

Release Date Price: $332.1

Transcript

Operator

Good afternoon, ladies and gentlemen. Welcome to the Sartorius and Sartorius Stedim Biotech conference call on the preliminary full year 2022 results. Today's conference is being recorded.

At this time, I would like to turn the conference over to Dr. Joachim Kreuzburg, CEO. Please go ahead, sir.

Joachim Kreuzburg

Sartorius Aktiengesellschaft - Chairman of Executive Board, CEO & Interim CFO

Thank you very much. Happy New Year, everyone, and welcome to our today's conference call on the preliminary results of the year 2022 for both Sartorius AG as well as the Sartorius Stedim Biotech. Thank you for your interest. Together with Rainer, our CFO, I will kick it off. We will first talk about the results of the Sartorius Group and then later on those of Sartorius Stedim Biotech. Let me start with a brief overview on the most important results for 2022. It has been another successful year after 2 years of very dynamic growth. We have been able to grow both divisions double digit. Overall, we met the targets that we tried to achieve, even though the Corona

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.